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Abstract
Introduction
 Lyme disease is the most common vector borne illness 
in the USA (Rebman et al., 2017).
 Lyme disease is endemic in the Northeast and upper 
Midwest states but can also be found along the Pacific 
coast (Rebman et al., 2017).
 Presenting symptoms include erythema migrans, Lyme 
arthritis, and cranial nerve palsy which are treated with 
doxycycline.  Hospitalization and IV ceftriaxone are often 
required for Lyme carditis and neurologic Lyme disease 
other than cranial nerve palsy (DynaMed Plus, Lyme 
disease., 2018).
 Misdiagnosis or inappropriate treatment may lead to an 
increase in likelihood of developing PTLDS.
Research Question




 Rebman et al. (2017) found that 59% of participants in the 
study with PTLDS were either misdiagnosed or diagnosis was 
delayed.  This stresses the importance of keeping Lyme 
disease in the differential diagnosis for typical symptoms 
occurring in endemic areas or those who have travelled to 
endemic areas.  
 Further research needs to be done to develop more specific 
and sensitive lab tests so that concrete diagnoses can be 
made when clinical symptoms are not as straight forward as 
erythema migrans.
In patients who were treated appropriately for Lyme disease but 
develop PTLDS, does extended course antibiotic therapy versus 
symptomatic treatment versus alternative treatments help 
relieve PTLDS symptoms most effectively?
• Numerous studies have shown that the use of extended 
antibiotics is not beneficial and increases the risk of adverse 
effects.
• There have been potential studies showing that alternative 
therapies may be something of use in the future.  Further 
research needs to be done to establish the efficacy on 
humans.
• That leaves the only option currently available as assessing 
every individual patient separately and treating the individual 
patient’s symptoms appropriately.  
– Fatigue, musculoskeletal pain, and cognitive difficulties are 
so similar to CFS that treatment options such as a healthy 
diet, exercise, counseling, acupuncture, and/or off-label use 
of methylphenidate may be appropriate.
– Dexamethasone for Lyme neuroborreliosis is recommended 
except in the case where facial palsy is present.
– NSAIDS and DMARDS  can be considered with persistent 
Lyme arthritis.
With the high incidence of Lyme disease in the endemic 
areas of North America, it is important to appropriately 
diagnosis and treat this condition to prevent post treatment 
Lyme disease syndrome (PTLDS).  Background information 
regarding Lyme disease is given.  The purpose of this 
research is to discuss the treatment options available for 
those patients that fit the case definition of PTLDS.  A 
literature review was conducted using several different 
electronic databases finding peer reviewed research 
articles pertaining to the treatment options available for 
PTLDS.  Extended antibiotic use is shown to be not 
beneficial in most cases.  Alternative treatment options 
listed on the internet are shown to be not evidence based.  
Therefore, symptomatic treatment options seem to be the 
best positive outcome-based option available for providers 
to use.  These options are discussed in detail throughout 
this research.  Though much more research is needed 
regarding the topic, this will give providers the information 
currently available that they will need to know when treating 
patients with PTLDS.  Hopefully this will provide the 
patients with PTLDS the best outcome possible for 
improving their quality of life post Lyme disease.
In patients who were treated appropriately for Lyme 
disease but develop PTLDS, does extended course 
antibiotic therapy versus symptomatic treatment versus 
alternative treatments help relieve PTLDS symptoms 
most effectively?
Evidence of PTLDS
 Infectious Diseases Society of America proposed a case 
definition for PTLDS in 2006 (Nemeth et al., 2016).
 Middelveen et al. (2018) confirms the presence of live 
Borrelia spirochetes with positive cultures in patients who 
were treated with antibiotics but remained symptomatic.
Treatment Options
Extended Antibiotic Use
 Studies going back to 2001 but most recently Berende et al. 
(2016) have shown that extended use of antibiotics does not 
improve symptoms more than the placebo groups 
(p=<0.001).
Based on Symptoms
Myalgic encephalomyelitis/chronic fatigue syndrome (CFS)
• Similarities between PTLDS and CFS suggest treatment of 
diet, exercise, counseling, acupuncture, and/or off-label use 
of methylphenidate may be beneficial (DynaMed Plus, 
chronic fatigue syndrome, 2018).
Lyme neuroborreliosis
 With triplicate data sets, Ramesh, Martinez, Martin, &Philipp 
(2017) showed that dexamethasone significantly reduced 
levels of Borrelia burgdorferi-induced inflammatory cytokines 
or chemokines over meloxicam (p<0.05, p<0.01, p<0.001).
Lyme disease-associated facial palsy
• Jowett, Gaudin, Banks, & Hadlock (2017) show worse 
outcomes when corticosteroids and antivirals are used with 
antibiotics versus monotherapy of antibiotics alone.
Lyme arthritis
 NSAIDS (ibuprofen or naproxen) and DMARDs 
(hydroxychloroquine or methotrexate) are shown to be 
effective after initial treatment (Arvikar & Steere, 2015)
Alternative Treatments 
• Lantos et al. (2015) showed that oxygen therapy, energy and 
radiation, metal chelation, nutritional supplements and 
biological therapies found on the internet through Google did 
not substantiate any efficacy in treatment of Lyme disease.
Essential oils
• Oregano and cinnamon bark showed remarkable activity for 
complete eradication of the stationary phase of Borrelia 
burgdorferi in animals (Feng et al., 2017).
Supplements
• Nicolson, Settineri, & Ellithorpe (2012) showed a 30.7% 
reduction in fatigue within 60 days of using a daily  ATP fuel 
supplement (p<0.001).
 PTLDS case definition (Nemeth et al., 2016, Table 1):
-An adult or child with a documented episode of early or 
late Lyme disease 
-Treatment with a generally accepted treatment regimen, 
with resolution of the objective manifestation
-Onset of any of the following subjective symptoms within 
6 months of the diagnosis and persistence of continuous 
or relapsing symptoms for at least 6 months after 
completion of antibiotic therapy:
Fatigue, widespread musculoskeletal pain, 
complaints of cognitive difficulties, or subjective 
symptoms with such severity that, when present, they 
result in substantial reduction in previous levels of 
occupational, educational, social or personal 
activities. 
 Extended use of antibiotics should not be prescribed.  
Patients must be warned that the efficacy of treatments 
listed on the internet are not evidence based and should 
be avoided.  Treating the patients according to their 
symptoms and following the recommended guidelines for 
each is the most effective form of treatment for PTLDS as 
of now.
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Statement of the Problem
Feng et al. (2017) have estimated that approximately 10-
20% of patients continue suffering from chronic symptoms 
described as PTLDS following the standard antibiotic 
treatment of 2-4 weeks for early or late Lyme disease.  The 
question remains that even if these symptoms are a direct 
or indirect consequence of Lyme disease, how can 
providers appropriately treat these patients.
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